Arzerra misses in DLBCL
Genmab A/S (CSE:GEN; OTCBB:GMXAY) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Arzerra ofatumumab plus chemotherapy missed the primary endpoint of improving progression-free survival (PFS) vs. Rituxan rituximab plus chemotherapy in the 447-patient Phase III ORCHARRD trial to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL). The companies said they are "unlikely to move forward" with regulatory filings for Arzerra in the indication.
GSK already markets Arzerra in the U.S. for first-line treatment of chronic lymphocytic leukemia (CLL) and in the U.S. and EU to treat CLL refractory to fludarabine and alemtuzumab. The pharma has worldwide co-development and commercialization rights to the human mAb against CD20 from Genmab, which was off DKK2.60 to DKK208.90 on Monday. The data came after market close in Denmark. ...